CJC-1295 (No DAC)
CJC-1295 (No DAC) is a modified 29-amino acid GHRH analog featuring four amino acid substitutions that enhance alpha-helical structure and confer 49x greater receptor potency versus native GHRH. Without the Drug Affinity Complex (DAC), this version exhibits a shorter half-life (~30 minutes) ideal for discrete pulsatile GH signal research. It functions as a potent GHRH receptor agonist, stimulating physiological growth hormone release patterns and subsequent IGF-1 production without affecting cortisol or prolactin levels. This makes it essential for endocrine research requiring precise temporal control over GH signaling and studies of anabolic, metabolic, and age-related processes.
CJC-1295 (No DAC) is a modified GRF(1-29), a 29-amino acid GHRH analog with four amino acid substitutions that enhance alpha-helical structure and confer 49x greater receptor potency versus native GHRH. The No DAC version features a shorter in vivo half-life (~30 minutes) designed for discrete pulsatile GH signal research, allowing researchers to study physiological growth hormone release patterns without the extended release profile of the DAC-modified version.
CJC-1295 functions as a potent GHRH receptor agonist, binding to and activating growth hormone-releasing hormone receptors on pituitary somatotroph cells. The four amino acid substitutions (Aib, Gln, Ala, and Leu at positions 2, 8, 15, and 27) protect against enzymatic degradation while maintaining receptor binding affinity. This structural modification results in significantly enhanced stability and bioavailability compared to unmodified GRF(1-29).
In research applications, CJC-1295 (No DAC) stimulates pulsatile growth hormone release, leading to increased IGF-1 production in hepatic and peripheral tissues. The absence of the Drug Affinity Complex (DAC) means the peptide does not bind to albumin for extended circulation, resulting in a more physiological release pattern that mimics natural GH pulsatility. This makes it particularly valuable for research protocols requiring precise temporal control over GH signaling.
The peptide demonstrates remarkable efficacy in stimulating GH release without significantly affecting cortisol, prolactin, or other stress hormone levels when used appropriately. This selectivity makes it a preferred research tool for studying GH axis function, anabolic processes, metabolic regulation, and age-related endocrine changes without confounding effects from other hormonal systems.
| Compound | MW / Formula | CAS No. | Sequence / Structure | Receptor / Target |
|---|---|---|---|---|
| CJC-1295 (No DAC) | ~3367 g/mol | 863288-34-0 | 29-AA GHRH fragment; 4× substitutions; 49× native GHRH potency | Modified GRF(1-29); GHRH receptor agonist |
The following compounds operate through distinct, non-overlapping mechanisms that complement this product's research pathways. Each is independently available from the General Peptide catalog.
Ipamorelin is a selective pentapeptide GHS-R1a (ghrelin receptor) agonist (CAS 170851-70-4; MW 711.9 g/mol) that functions through Ca2+/IP3 signaling to stimulate pulsatile growth hormone release. As the most selective GHRP available, it does n...
This triple-blend combines two Growth Hormone Releasing Hormones (Tesamorelin, CJC-1295) with a selective ghrelin mimetic (Ipamorelin) to maximize pulsatile GH secretion. By targeting pituitary somatotrophs through distinct pathways, it synergi...
MOTS-c is a unique 16-amino acid peptide encoded by the mitochondrial genome rather than nuclear DNA. It functions as a potent metabolic regulator and "exercise mimetic" by translocating to the nucleus to activate AMPK, optimizing cellular ener...
Retatrutide (LY3437943) is an advanced 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple-agonist action coordinates appetite suppression, enhanced insulin dynamics, and increased hepat...
NAD+ is a vital dinucleotide coenzyme present in all living cells, central to cellular energy, DNA repair, and signaling. It fuels ATP production and acts as the rate-limiting substrate for Sirtuins, PARPs, and CD38 enzymes. Because NAD+ levels...